Monitor Motor Symptoms with Telemedicine
Kinesia technology works to increase sensitivity and minimize variability of clinical trial data
Significant controversy regarding results, as seen in high-profile clinical trials for Parkinson’s disease drugs, has become an obstacle for bringing new treatments to market. Designing a protocol to demonstrate changes in OFF or ON times, quantify dyskinesia, or accurately measure neuroprotective effects can be incredibly challenging. Kinesia technology aims to meet this challenge through improving sensitivity and minimizing variability of symptom measurements, which can make results that previously had confounding factors significant when the noise is removed.
Kinesia technology, for objective Parkinson’s assessment, aims to magnify the differences between treatments, if they exist, and minimize the variability in the resulting data.
Objective Parkinson’s Measurements
Part of the industry’s challenges lie in the traditional tools used to measure these clinical outcomes; subjective rating scales and patient diaries have limited sensitivity and reliability that may confound results. An improvement in the measurement sensitivity and reliability decreases costs and number of required patients for a clinical trial, minimizing risks to human subjects, and speeding time to market.